AS 602801

• CAT Number: I005085
• CAS Number: 848344-36-5
• Molecular Formula: C₂₅H₂₃N₅O₂S
• Molecular Weight: 457.55
• Purity: ≥95%
• Synonyms: 2-(1,3-benzothiazol-2-yl)-2-[2-[[4-(morpholin-4-ylmethyl)phenyl]methoxy]pyrimidin-4-yl]acetonitrile
• Target: JNK
• Solubility: DMSO：10.8 mg/mL
• Storage: Store at -20°C
• InChI: InChI=1S/C25H23N5O2S/c26-15-20(24-28-22-3-1-2-4-23(22)33-24)21-9-10-27-25(29-21)32-17-19-7-5-18(6-8-19)16-30-11-13-31-14-12-30/h1-10,20H,11-14,16-17H2
• InChIKey: XCPPIJCBCWUBNT-UHFFFAOYSA-N
• SMILES: C1COCCN1CC2=CC=C(C=C2)COC3=NC=CC(=N3)C(C#N)C4=NC5=CC=CC=C5S4

AS 602801（Cat No.:I005085）, also known as TAS 602, is a potent and selective inhibitor of Janus kinase 2 (JAK2). JAK2 is a key player in the JAK/STAT signaling pathway, which is involved in cytokine signaling, inflammation, and immune responses. By inhibiting JAK2, AS 602801 is used in research to explore therapeutic interventions for diseases related to dysregulated cytokine signaling, such as myeloproliferative disorders, autoimmune diseases, and certain cancers. Its ability to modulate the JAK/STAT pathway makes it a valuable tool for investigating targeted therapies in both oncology and immunology research.

Reference

[1]. Ferrandi C, Richard F, Tavano P, Hauben E, Barbié V, Gotteland JP, Greco B, Fortunato M, Mariani MF, Furlan R, Comi G, Martino G, Zaratin PF. Characterization of immune cell subsets during the active phase of multiple sclerosis reveals disease and c-Jun N-terminal kinase pathway biomarkers. Mult Scler. 2011 Jan;17(1):43-56.